AEQUITAS HEALTH

SreyRam Kuy, MD, MHS, is a practicing general surgeon and the deputy chief medical officer for quality and safety of a network of VA medical centers and facilities. SreyRam previously served as special advisor to the Secretary of the VA and was the first woman appointed deputy under secretary for community care, overseeing a $14.5 billion budget and 7,300 staff. Before that, SreyRam served as chief medical officer for Louisiana Medicaid, a $10.7 billion system covering 1.6 million children, pregnant women, and disabled and indigent patients. In this role, she instituted quality performance metrics and payment reforms and led initiatives tackling the opioid crisis, resulting in a 40% reduction in new opioid prescriptions. SreyRam is the recipient of the American College of Surgeons Inspiring Woman in Surgery Award, President George H.W. Bush’s Points of Lights Award, Oregon Health Sciences University Early Career Achievement Award, L’Oréal Paris Women of Worth, and Business Report’s 40 Under 40 and was named by Modern Healthcare as one of ten Minority Healthcare Executives to Watch. She was a Presidential Leadership Scholar through a bipartisan leadership program taught by Presidents George W. Bush, Bill Clinton, and George H. W. Bush, a Robert Wood Johnson Clinical Scholar, a Kaiser Family Foundation Health Policy Scholar in the US Senate, an Eisenhower Fellow, and an American College of Surgeons Health Policy Scholar. SreyRam received her MD from Oregon Health Sciences University and her master’s degree from Yale. She is the author of 50 Studies Every Surgeon Should Know and is published widely on health policy, quality, and safety and has written for the Washington Post, USA Today, Los Angeles Times, and Huffington Post. SreyRam is a Fellow of the fifth class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.

Greg Yap, MBA, is a partner at Menlo Ventures, where he invests in teams trying to solve major problems in life science and healthcare, with a special interest in novel therapeutic platforms, patient-focused digital health, and transformative technologies. Previously, Greg was an entrepreneur-in-residence at Illumina Ventures, where he focused on new investments related to genomics. Prior to entering venture capital, Greg had 20 years of experience in senior executive and entrepreneurial roles in life science and digital health. He was CEO and co-founder of two startups: Biodesy, a next generation protein analysis company, and PyrAmes, a digital health remote monitoring company. At Roche Diagnostics/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million revenue per year. Greg’s operating experience also includes roles as the first healthcare entrepreneur-in-residence at GE; chief operating officer at Cellpoint Diagnostics, an early liquid biopsy startup; vice president and general manager for genetics and molecular diagnostics at Affymetrix, the microarray genomics pioneer; and consultant for McKinsey & Company. He also serves on the board of Outward Bound California. Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton University and his MBA from Stanford University’s Graduate School of Business. Greg’s current investments include Clear Labs, Encoded Therapeutics, Epiodyne, Pliant Therapeutics, Sana Health, and Senti Bio. He is a San Francisco Bay Area native and lives in Palo Alto, CA, with his wife and children. Greg is a Fellow of the fifth class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.